Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Closed 12-11 16:00:00 EST

71.23

+0.37

+0.53%

High71.50	Low70.75	Vol692.40M
Open70.86	D1 Closing70.86	Amplitude1.05%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O15.16B	T/O Rate--	Tradable Shares0.00
P/B7.03811	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":71.23319,"timestamp":1765486799999,"preClose":70.85921,"halted":0,"volume":692402249,"delay":0,"changeRate":0.005278,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":0.373985,"latestTime":"12-11 16:00:00 EST","open":70.859055,"high":71.4989,"low":70.75221,"amount":15162782899.274239,"amplitude":0.010538,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.03811,"peRate":-124.516039,"turnoverRate":0.02148,"increases":253,"decrements":254,"flats":16,"marketCap":1852064321638.875,"floatMarketCap":1657126687491.875},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2590546249","title":"BRIEF-Alphaton Capital Corp Announces Data Center Agreement With atNorth","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546249","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546249?lang=en_us&edition=fundamental","pubTime":"2025-12-12 04:29","pubTimestamp":1765484957,"startTime":"0","endTime":"0","summary":"BRIEF-Alphaton Capital Corp Announces Data Center Agreement With atNorthDec 11 (Reuters) - AlphaTON Capital Corp ATON.O:ALPHATON CAPITAL CORP ANNOUNCES FIRST MAJOR DATA CENTER AGREEMENT WITH ATNORTH, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA2MJ0WY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATON","BK4139"],"gpt_icon":0},{"id":"2590546572","title":"Lixte Biotechnology Holdings Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546572?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:52","pubTimestamp":1765482745,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. held its Annual Meeting on December 8, 2025. Shareholders approved the election of Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, and Guy Primus to the board of directors. The appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved an amendment to the 2020 Plan, increasing the number of shares of common stock available for issuance from 2.75 million to 3.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLCR9SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2590317546","title":"AlphaTON Capital Corp Secures 2.2 MW Data Center Agreement with atNorth in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2590317546","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590317546?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:44","pubTimestamp":1765482291,"startTime":"0","endTime":"0","summary":"AlphaTON Capital Corp. announced it has entered into a 60-month Enterprise Colocation Service Agreement with atNorth AB, a European data center operator. Under the agreement, starting February 1, 2026, AlphaTON will secure 2,230 kW of peak power capacity at atNorth's Tier 3 certified SWE01 facility in Kista, Sweden, with a right of first refusal for an additional 2,100 kW. The agreement will provide AlphaTON with the infrastructure to deploy over 2,000 high-performance GPUs, supporting the company's expansion in decentralized AI computing and related services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlphaTON Capital Corp. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLVrq7v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014039.USD","ATON","BK4585","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","BK4139","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2590463145","title":"Alphaton Capital Corp Announces First Major Data Center Agreement With Atnorth, Securing 2.2 Mw of High-Performance Computing Capacity in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2590463145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590463145?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:44","pubTimestamp":1765482280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA2MJ0WY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATON","BK4139"],"gpt_icon":0},{"id":"2590354658","title":"Alphaton Capital Corp -Under Terms of Deal,  to Secure 2,230 Kw Capacity in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2590354658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590354658?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:44","pubTimestamp":1765482280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA2MJ0WY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATON"],"gpt_icon":0},{"id":"2590546894","title":"Celcuity Reports Positive Phase 3 Results for Gedatolisib in Advanced Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546894","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546894?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:35","pubTimestamp":1765481714,"startTime":"0","endTime":"0","summary":"Celcuity Inc., a clinical-stage biotechnology company, announced updated results from the randomized, Phase 3 VIKTORIA-1 trial evaluating gedatolisib, a pan-PI3K and mTORC1/2 inhibitor, in adults with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative , PIK3CA wild-type advanced breast cancer. The data were presented at the 2025 San Antonio Breast Cancer Symposium. Results showed that, for patients whose time to progression on prior therapy exceeded 18 months, the median progression-free survival  was 12.4 months for the gedatolisib triplet , 10.0 months for the gedatolisib doublet , and 1.9 months for fulvestrant alone. Among patients in the U.S., Canada, Western Europe, and Asia Pacific, the median PFS was 16.6 months with the triplet regimen and 7.1 months with the doublet, compared to 1.9 months for fulvestrant. Measures to mitigate stomatitis were generally effective, with most patients experiencing resolution to a lower grade within two weeks.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL25pc6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014013.SGD","CELC","BK4112","SG9999014005.SGD","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","BK4139","LU2210149790.SGD","IE00B64PRP62.GBP","BK4588","BK4585","NDAQ"],"gpt_icon":0},{"id":"2590546882","title":"Celcuity Presents Updated Results From the Pik3CA Wild-Type Cohort of the Phase 3 Viktoria-1 Trial at the 2025 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546882?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:35","pubTimestamp":1765481700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA6FRZ0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELC","BK4139"],"gpt_icon":0},{"id":"2590545749","title":"US senators push USDA for urgent action on bird flu vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545749?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:19","pubTimestamp":1765480772,"startTime":"0","endTime":"0","summary":"UPDATE 1-US senators push USDA for urgent action on bird flu vaccineSenators tell USDA to prioritize science in bird flu vaccine developmentUSDA pledged $100 million for bird flu vaccine research in MarchPoultry industry divided on vaccination due to trade concernsAdds USDA comment in paragraph 6By Leah Douglas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","BK4501","BK4548","BK4533","BK4534","BK4568","BK4139","BK4551","BK4588","BK4585","BK4532"],"gpt_icon":0},{"id":"2590545243","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545243","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545243?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:19","pubTimestamp":1765480747,"startTime":"0","endTime":"0","summary":"Rezolute  reported Thursday that a phase 3 study, evaluating ersodetug in patients with congenital hyperinsulinism, failed to meet its primary or key secondary endpoints.Shares of the company plunged 87% as intraday trading volume jumped to over 100.6 million from a daily average of about 1.6 million.ChowChow Cloud International  reported on Thursday unusual trading activity in its ordinary shares on the NYSE American on Dec. 10 and 11.The company said \"there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action.\"Shares of ChowChow slumped 36% as intraday trading volume soared to over 7.2 million from a daily average of about 1 million.Oracle's  fiscal Q2 sales missed revenue expectations, as it reported a negative free cash flow of $10 billion and guided a $15 billion increase in its capital expenditure forecast for fiscal 2026.Shares of the tech giant dropped 11% as intrada","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0157215616.USD","LU0082616367.USD","LU0208291251.USD","LU0648001328.SGD","LU1435385759.SGD","LU1989772923.USD","LU2237957811.SGD","LU2458330243.SGD","LU1548497426.USD","BK4516","LU0109392836.USD","LU0444971666.USD","LU0738911758.USD","LU0070302665.USD","BK4534","LU0889565833.HKD","LU1506573853.SGD","IE00B3S45H60.SGD","LU1934455863.HKD","LU1935042215.USD","LU2458330169.SGD","LU0553294199.USD","LU1035773651.USD","LU0056508442.USD","LU0661504455.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1934455277.USD","BK4538","IE00BBT3K403.USD","LU0433182093.SGD","LU1037948897.HKD","LU0210536198.USD","LU0234570918.USD","LU2896262040.SGD","BK4543","SG9999001424.SGD","LU0348723411.USD","LU0878866978.SGD","LU2746668461.USD","BK4139","BK4581","LU0949170772.SGD","LU0957808578.USD","LU2108987350.USD","IE00BMPRXN33.USD","LU1366192091.USD","LU1429558221.USD","LU2860962120.EUR","LU1037948541.HKD","LU0353189763.USD","LU0289960550.SGD","LU0417517546.SGD","LU0965508806.USD","IE00BMPRXQ63.HKD","LU2250418816.HKD","LU0081259029.USD","LU1852331112.SGD","LU0353189680.USD","IE0004445239.USD","LU1720051017.SGD","IE00BMPRXR70.SGD","LU1935042488.USD","LU0198837287.USD","LU1989772840.SGD","IE00BLSP4452.SGD","LU1803068979.SGD","LU0985489474.SGD","SG9999011175.SGD","LU1366333091.USD","LU1935043023.USD","LU0444973449.USD","LU2360106780.USD","BK4585","SG9999003800.SGD","LU1003077747.HKD","LU1934455194.USD","LU2087625088.SGD","IE00B775SV38.USD","BK4097","LU0323591593.USD","IE00B7SZLL34.SGD","LU2543165471.USD","LU1989764664.SGD","LU0719512351.SGD","LU2054465674.USD","BK4588","LU1935042991.SGD","RZLT","IE00BN8TJ469.HKD","LU0965509010.AUD","LU1489326972.SGD","LU0545039389.USD","IE00BLSP4239.USD","LU1642822529.SGD","LU2236285917.USD","LU1691799644.USD","LU0320765489.SGD","LU0965509101.SGD","IE0009356076.USD","LU2357305700.SGD","IE00B5949003.HKD","LU0980610538.SGD","BK4134","LU0068578508.USD","LU1989764748.USD","LU2326559502.SGD","LU0130102774.USD","LU0965509283.SGD","LU0314106906.USD","LU0476273544.USD","LU1815336760.USD","BK4533","LU1069347547.HKD","LU2746668974.SGD","BK4528","LU0861579265.USD","LU0256863811.USD","LU2237957902.USD","LU0175139822.USD","LU1935043536.SGD","LU1720051108.HKD","IE0002270589.USD","LU1201861249.SGD"],"gpt_icon":1},{"id":"2590545106","title":"Ovid Therapeutics Inc. Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545106?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:59","pubTimestamp":1765479550,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics Inc. held a special meeting of stockholders on December 11, 2025. Stockholders approved an increase in authorized shares of common stock from 125,000,000 to 315,000,000. Approval was also granted for the issuance of shares of common stock upon the conversion of Series B Preferred Stock and the exercise of related warrants. In addition, the issuance and sale of preferred stock and warrants to the Chief Executive Officer was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbHFYCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OVID"],"gpt_icon":0},{"id":"2590545996","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545996?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:54","pubTimestamp":1765479240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 13:54 ET (18:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","RYTM","BK4585"],"gpt_icon":0},{"id":"2590545151","title":"Roivant Signals Major Pipeline Momentum With Accelerated Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545151","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545151?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:39","pubTimestamp":1765478340,"startTime":"0","endTime":"0","summary":"Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49344150/roivant-signals-major-pipeline-momentum-with-accelerated-timelines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49344150/roivant-signals-major-pipeline-momentum-with-accelerated-timelines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4532","IMVT","BK4555","BK4585","BK4551","BK4501","NIU","BK4550","BK4187","BK4533","BK4588","BK4568","BK4558","DM","BK4516","BK4091","BK4546","ROIV","BK4161","LU0170899867.USD","BK4139","BK4534","MRNA","BK4548","GD","BK4007","BK4566"],"gpt_icon":0},{"id":"2590543792","title":"Why Is XOMA Royalty Stock Sinking Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543792","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543792?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:09","pubTimestamp":1765476540,"startTime":"0","endTime":"0","summary":"XOMA stock plunged after its partner Rezolute Inc. reported disappointing trial results for their product Ersodetug.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49343120/why-is-xoma-royalty-stock-sinking-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49343120/why-is-xoma-royalty-stock-sinking-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["RZLT","LU0128526141.USD","XOMA","LU2125154778.USD","HI","LU0029874061.USD","BK4139","LU2360032135.SGD","LU2125154935.USD","BK4161"],"gpt_icon":0},{"id":"2590154348","title":"MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154348","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:00","pubTimestamp":1765476000,"startTime":"0","endTime":"0","summary":"CHICAGO, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), ap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204217/0/en/MAIA-s-Ateganosine-Surges-Ahead-with-Breakthrough-Momentum-as-Pivotal-Phase-3-Trial-Initiates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2590433905","title":"Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590433905","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590433905?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:33","pubTimestamp":1765474380,"startTime":"0","endTime":"0","summary":"Rezolute sinks after its Phase 3 congenital hyperinsulinism trial showed no statistically significant benefit for ersodetug despite favorable safety data.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Female-Scientist-Working-In-The-Lab--She.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Female-Scientist-Working-In-The-Lab--She.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0029874061.USD","HI","LU2360032135.SGD","LU0128526141.USD","LU2125154778.USD","RZLT","BK4161","LU2125154935.USD","BK4139"],"gpt_icon":0},{"id":"2590543838","title":"Crude Oil Down 2%; Ciena Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543838","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543838?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:27","pubTimestamp":1765474054,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49341587/crude-oil-down-2-ciena-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0965509101.SGD","LU0256863811.USD","LU0878866978.SGD","BK4020","BK4585","LU0154245756.USD","LU1366192091.USD","IE00BMPRXQ63.HKD","LU0082616367.USD","LU1934455277.USD","LU0965508806.USD","BK4196","LU0476273544.USD","LU0070302665.USD","LU2236285917.USD","LU1989764748.USD","LU1506573853.SGD","LU1803068979.SGD","BK4123","BK4581","LU1934455863.HKD","LU1989772923.USD","LU2326559502.SGD","LU1069347547.HKD","LU2357305700.SGD","LU0353189763.USD","LU0661504455.SGD","LU0965509283.SGD","BK4543","LU1435385759.SGD","LU2896262040.SGD","LU1035773651.USD","LU0109392836.USD","LU1691799644.USD","LU2108987350.USD","LU2746668461.USD","BK4139","LU0719512351.SGD","BK4021","LU0106261612.USD","LU0348723411.USD","LU0985489474.SGD","LU0289960550.SGD","LU1815336760.USD","IE00B19Z3581.USD","LU1720051108.HKD","LU0980610538.SGD","LU0553294199.USD","LU0323591593.USD","LU2054465674.USD","LU1429558221.USD","SG9999011175.SGD","LU0957808578.USD","LU1935042488.USD","LU1935042215.USD","LU0320765489.SGD","IE00B5949003.HKD","LU2458330169.SGD","IE0004445239.USD","LU0417517546.SGD","LU0154245673.USD","LU1935043536.SGD","LU1989764664.SGD","IE00BLSP4452.SGD","SG9999001424.SGD","LU1201861249.SGD","IE00B7SZLL34.SGD","LU1935042991.SGD","BK4528","LU0433182093.SGD","BK4134","LU1037948541.HKD","LU0205193047.USD","LU0234570918.USD","LU0353189680.USD","LU1935043023.USD","LU0198837287.USD","LU2360106780.USD","IE00BN8TJ469.HKD","LU0444971666.USD","LU0205194284.USD","LU0648001328.SGD","LU1548497426.USD","LU0068578508.USD","LU1720051017.SGD","IE00BBT3K403.USD","CIEN","LU2250418816.HKD","LU2543165471.USD","LU0889565833.HKD","LU2087625088.SGD","IE00B775SV38.USD","LU0208291251.USD","LU0154236417.USD","LU1003077747.HKD","BK4007","IE00BMPRXR70.SGD","BK4135","BK4182","LU0240878834.USD","LU1642822529.SGD","LU2458330243.SGD","LU0210536198.USD","LU0130102774.USD","LU0949170772.SGD","IE00BMPRXN33.USD","LU0545039389.USD","LU2860962120.EUR","IE00B3S45H60.SGD","LU0823421333.USD","LU1489326972.SGD","BK4516","LU0965509010.AUD","LU2237957902.USD","LU0157215616.USD","LU0240877869.USD","LU0314106906.USD","BK4538","LU0861579265.USD","LU0738911758.USD","LU1989772840.SGD","LU0012050646.USD","LU0963586101.USD","LU2746668974.SGD","LU1366333091.USD","SG9999003800.SGD","LU0081259029.USD","BK4588","BK4097","LU0444973449.USD","IE0002270589.USD","LU0056508442.USD","BK4534","LU0175139822.USD","LU1852331112.SGD","LU1934455194.USD","IE0009356076.USD","IE00BLSP4239.USD","BK4129","BK4533","LU0823421416.USD","BK4515","LU1037948897.HKD","LU2237957811.SGD"],"gpt_icon":0},{"id":"2590543348","title":"Why Are Shares Of Atossa Therapeutics Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543348","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:26","pubTimestamp":1765473960,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4548","BK4007","BK4139","BK4551","BK4585","ATOS","BK4539","Z","BK4079","LENZ","BK4588"],"gpt_icon":0},{"id":"2590548415","title":"Incyte's Blood Cancer Drug Program 'Looks Very Viable' Amid Development Challenges, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590548415","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590548415?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:14","pubTimestamp":1765473283,"startTime":"0","endTime":"0","summary":"Incyte  is seeing results from its INCA033989 blood cancer drug program that seem to indicate the drug \"looks very viable, safe\" and may have \"unique disease-modifying properties,\" RBC Capital Markets said in a note Thursday, following meetings with the company's senior management.However, optimizing the drug's dosing levels, its administration, and the design of a phase 3 trial may \"be slightly more tedious than earlier Street exuberance had considered,\" RBC said.Incyte recently released updated clinical data from two phase 1 studies assessing the safety, tolerability and efficacy of INCA033989 to treat people with mutCALR-expressing myeloproliferative neoplasms.RBC said that it still believes the program has a good probability of success but a \"smaller ultimate opportunity than consensus.\"The investment firm said Incyte's shares \"approximately fairly reflect [near-term] cash flows.\"RBC has a sector perform rating on Incyte and an $84 price target.Price: 95.75, Change: +0.58, Percent ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4588","BK4550","BK4139","INCY","BK4585"],"gpt_icon":0},{"id":"2590484375","title":"Ultragenyx CFO Howard Horn Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590484375","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590484375?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:10","pubTimestamp":1765473053,"startTime":"0","endTime":"0","summary":"Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL21bLpv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ultragenyx CFO Howard Horn Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2590107925","title":"Top Midday Stories: Oracle Shares Tumble After Revenue Miss; Lilly's Next-Gen Weight-Loss Drug Hits Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2590107925","media":"MT Newswires Live","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590107925?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:36","pubTimestamp":1765471004,"startTime":"0","endTime":"0","summary":"The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were also lower in late-morning trading Thursday, as Oracle's (ORCL) earnings report dragged down tech stocks despite ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0072461881.USD","LU2430703251.USD","LU2317271919.USD","LU0689626769.HKD","LU1235294995.USD","IE00BK4W5M84.HKD","LU0432979614.USD","IE00BFSS7M15.SGD","LU2092937148.SGD","LU1670710588.SGD","LU2095319765.USD","LU0511384066.AUD","LU2430703178.SGD","IE00BJJMRZ35.SGD","LU1032955483.USD","LU0724617625.USD","LU0323239441.USD","LU0957808578.USD","LU2237438978.USD","BK4585","LU2211815571.USD","LU0210533765.USD","LU1035775433.USD","LU2461242641.AUD","LU0323240290.USD","LU0345770993.USD","LU0683600562.USD","LU0878866978.SGD","LU1046421795.USD","LU1720051017.SGD","LU0289961442.SGD","LU1868837136.USD","ORCL","LU2083900584.USD","LU2506952097.USD","IE00BYQQ9H92.USD","LU0553294199.USD","IE00BJLML261.HKD","LU2097344431.USD","LU0127658192.USD","LU0234572021.USD","LU0823434740.USD","LU0426412945.USD","IE0004091025.USD","LU2347655156.SGD","LU0557290698.USD","DIS","LU1069344957.HKD","SGXZ57979304.SGD","LU2552382215.SGD","LU0077335932.USD","LU0994945656.USD","LU0786609619.USD","SGXZ99366536.SGD","LU0310800379.SGD","LU0354030511.USD","LU1429558221.USD","LU1989772840.SGD","LU0210536198.USD","LU1670628061.USD","LU1989771016.USD","IE00BDRTCR15.USD","LU1823568750.SGD","LU2108987350.USD","LU0048573561.USD","LU0158827948.USD","LU1116320901.HKD","LU1732799900.SGD","BK4576","IE0004445239.USD","LU0053666078.USD","BK4023","LU1061106388.HKD","LU0823434583.USD","LU2505996509.AUD","LU1839511570.USD","LU0215105999.USD","BK4548","LU1066051811.HKD","LU2148611432.USD","LU2764262908.HKD","IE00B4R5TH58.HKD","LU0784385840.USD","LU1037948541.HKD","LU1119994496.HKD","LU2326559502.SGD","LU2298321311.HKD","LU0640476718.USD","IE00B2B36J28.USD","IE00BLSP4239.USD","LU0726765562.USD","LU0942090050.USD","LU0308772762.SGD","LU2087625088.SGD","LU2125909593.SGD","LU2404859667.USD","LU2237957811.SGD","LU1121112475.USD","LU1228905540.USD","LU2125909247.SGD","LU2168563687.JPY","LU0320765059.SGD","LU2087621335.USD","LU2077746001.SGD","LU2089984988.USD","LU0048584097.USD","LU2168564149.EUR","IE000W1ABFV2.USD","SG9999002232.USD","IE0034235188.USD","LU0198837287.USD","LU0203201768.USD","LU0225283273.USD","LU0109391861.USD","LU0471298694.HKD","LU2237443978.SGD","LU0889565833.HKD","LU2237443895.HKD","LU0094547139.USD","LU2361044865.SGD","LU0494093205.USD","LU0689472784.USD","IE0009356076.USD","IE00B1XK9C88.USD","BK4554","LU1791710582.SGD","LU0861579265.USD","LU0203202063.USD","LU2324357040.USD","LU1267930730.SGD","LU2242649171.HKD","IE00B4YYXB79.USD","IE00BKVL7J92.USD","LU2471134879.HKD","LU0882574055.USD","SG9999011175.SGD","IE00BZ1G4Q59.USD","LU0251142724.SGD","BK4504","LU1221951046.USD","LU1235295455.SGD","LU0889566641.SGD","LU1291159041.SGD","LU1720051108.HKD","LU0347712357.USD","BK4577","LU2242650005.HKD","LU0820561909.HKD","LU0345774631.USD","IE00BJTD4N35.SGD","LU0985489474.SGD","BK4599","SG9999015952.SGD","LU1815336760.USD","LU1188199696.SGD","LU0210528500.USD","LU2168564222.USD","LU1989763005.USD","LU0061474960.USD","LU2275660780.HKD","LU0107464264.USD","LU1935043536.SGD","LU0056508442.USD","LU1778281490.HKD","IE0004445015.USD","LU0096364046.USD","IE00BSNM7G36.USD","LU0265550359.USD","SG9999014542.SGD","LLY","SG9999015341.SGD","LU0011850046.USD","SG9999004303.SGD","IE00B19Z8X17.USD","LU2357305700.SGD","IE00BMPRXN33.USD","IE00BJJMRY28.SGD","LU0068578508.USD","BK4532","LU2028103732.USD","SG9999015945.SGD","IE00BJTD4V19.USD","IE00B1BXHZ80.USD","LU1983299246.USD","LU1670711123.USD","LU2452424414.USD","LU1633808545.USD","LU2750360997.AUD","LU2265009873.SGD","LU2362540622.SGD","LU0672654240.SGD","GB00B4LPDJ14.GBP","LU2279689827.SGD","LU0149725797.USD","LU0889565916.HKD","LU2458330243.SGD","IE00BQXX3F31.USD","LU1861127337.USD","IE00B7SZLL34.SGD","LU1585245621.USD","LU1057294990.SGD","LU1035773651.USD","LU2433249047.HKD","LU2552382132.HKD","LU0433182093.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","LU2750360641.GBP","LU2092627202.USD","SG9999001424.SGD","LU0466842654.USD","IE00B7KXQ091.USD","LU2756315318.SGD","BK4543","LU2271345857.HKD","LU1261432733.SGD","LU0528227936.USD","GB00B4QBRK32.GBP","LU0708994859.HKD","LU2168564065.EUR","LU0171293334.USD","LU0070302665.USD","LU2417539215.USD","LU2487616109.SGD","LU2237957902.USD","BK4097","LU1564329032.USD","LU0122379950.USD","LU0471298777.SGD","IE0001KFT4U8.USD","LU0314106906.USD","LU0070217475.USD","IE00BJJMRX11.SGD","LU1323610961.USD","LU0323591593.USD","LU0082616367.USD","LU0757359368.USD","LU0061475181.USD","SGXZ81514606.USD","LU2347655073.USD","LU1116320737.USD","LU0965509283.SGD","LU0345774391.USD","LU0096362180.USD","LU0426417589.USD","LU1934455863.HKD","BK4561","LU2468319806.SGD","LU1974910355.USD","LU0820562030.AUD","LU1093756325.SGD","LU2286300806.USD","IE00BLSP4452.SGD","LU1670627923.USD","LU0265550946.USD","BK4527","LU0784383803.USD","LU2456880835.USD","LU1228905037.USD","SG9999014906.USD","BK4139","LU2592432038.USD","LU1923622614.USD","LU2860962120.EUR","LU0251132253.USD","LU2381873111.SGD","LU1868836591.USD","LU0354030438.USD","SG9999014575.USD","BK4535","LU1803068979.SGD","BK4516","LU0276348264.USD","LU2360032135.SGD","LU1064131342.USD","LU1267930813.SGD","LU0957791311.USD","LU0342679015.USD","IE00BKPKM429.USD","LU1548497426.USD","LU1551013425.SGD","LU0251131958.USD","LU1732800096.USD","SG9999015986.USD","LU1280957306.USD","LU2462157665.USD","IE000KEQY171.SGD","LU2112291526.USD","IE000ITXATA3.USD","LU2125154935.USD","LU2089283258.USD","LU2404859741.USD","IE00BKDWB100.SGD","LU0965509010.AUD","LU1935042215.USD","SG9999015978.USD","SG9999003800.SGD","LU0345770308.USD","LU0787776722.HKD","LU1935043023.USD","BK4566","LU1489326972.SGD","LU1914381329.SGD","LU0950375773.USD","IE00BDCRKT87.USD","LU0158827781.USD","LU1712237335.SGD","IE00BHPRN162.USD","IE00BMPRXQ63.HKD","LU1340139317.AUD","LU0390134368.USD","SG9999018857.SGD","LU0114720955.EUR","LU1629891620.HKD","LU0162691827.USD","BK4538","LU2471134952.CNY","LU0661504455.SGD","LU1366333091.USD","LU1582986433.USD","LU1582987597.SGD","BK4598","SGXZ23171101.USD","LU1989772923.USD","LU2023250504.SGD","LU0256863811.USD","IE00B19Z3581.USD","SG9999001077.SGD","LU0985320562.USD","GB00BDT5M118.USD","LU1059921491.USD","LU1244550494.USD","LU1145028129.USD","LU1232071149.USD","IE00B5TLWC47.USD","LU0385154629.USD","LU2420271590.USD","LU1236620750.USD","LU2543165471.USD","IE00B4JS1V06.HKD","IE00BFSS8Q28.SGD","LU1670710661.SGD","LU1934455194.USD","LU0124676726.USD","LU0545562505.USD","LU2764263203.CNY","LU0211327993.USD","LU2210150020.SGD","LU0289941410.SGD","LU2360106780.USD","LU0868494708.USD","IE0004086264.USD","LU2720916845.USD","SGXZ31699556.SGD","BK4587","LU0154236417.USD","LU0316494557.USD","LU1868836757.USD","LU1582986359.USD","LU1623119135.USD","LU0081259029.USD","IE00B5949003.HKD","LU0006306889.USD","LU0061474705.USD","IE00B19Z8W00.USD","LU2413666699.HKD","LU2054465674.USD","LU1934455277.USD","LU0912757837.SGD","LU2191332357.HKD","LU0266013472.USD","LU2491049909.HKD","LU1074936037.SGD","LU2237443465.HKD","BK4592","LU1066053197.SGD","LU1496350502.SGD","LU0738911758.USD","SG9999001176.USD","BK4551","LU0648001328.SGD","LU0788109477.HKD","LU0964807845.USD","LU0456855351.SGD","LU0289739343.SGD","LU1066051498.USD","BK4567","LU1435385759.SGD","LU2362541273.HKD","LU2361045086.USD","LU0894485498.HKD","LU2065171311.SGD","LU2360106947.USD","LU2168564495.EUR","LU0079474960.USD","SG9999001176.SGD","LU0345768740.USD","LU1917777945.USD","LU0345769128.USD","SG9999018865.SGD","LU0345768153.USD","LU0820561818.USD","LU0302445910.USD","LU0868494617.USD","LU2133065610.SGD","LU1084165304.USD","LU1868836914.USD","IE00BBT3K403.USD","LU1221951129.SGD","LU2111349929.HKD","LU2065171402.SGD","LU1791710400.SGD","LU0894486033.HKD","LU1127390331.HKD","BK4108","LU1935042991.SGD","LU2430703095.HKD","LU1564329628.SGD","IE0005OL40V9.USD","LU1804176565.USD","IE00BQXX3D17.EUR","LU0417517546.SGD","LU2403377893.USD","BK4528","LU2506951875.HKD","LU1043141396.HKD","LU2602419157.SGD","LU0708995401.HKD","LU1093756168.USD","LU0444971666.USD","IE00BFXG0V08.USD","LU0058720904.USD","BK4588","SG9999014559.SGD","LU1674673428.USD","IE0003U64NQ7.SGD","LU0444973449.USD","IE00BK4W5L77.USD","LU0795875086.SGD","IE0034235303.USD","LU2237443622.USD","IE00B3S45H60.SGD","SG9999015358.SGD","LU1196500208.SGD","LU1814569148.SGD","LU1201861249.SGD","LU0757359954.USD","LU0072462426.USD","LU1691799644.USD","BK4550","LU1815333072.USD","LU2237443549.SGD","LU2106854487.HKD","IE00B775H168.HKD","LU0109394709.USD","SG9999014567.USD","LU0823417737.USD","LU0960925559.SGD","LU0097036916.USD","LU1181866309.USD","IE00BYXW3230.USD","LU1244550577.SGD","LU2244417387.USD","LU1267930573.SGD","LU2250418816.HKD","LU0208291251.USD","IE00B3SWFQ91.USD","LU1032466523.USD","LU2237443382.USD","BK4581","LU0057025933.USD","BK4612","LU0238689110.USD","LU0314104364.USD","SG9999013999.USD","LU0095938881.EUR","LU2264538146.SGD","IE00BQXX3C00.GBP","LU2063271972.USD","LU2505996681.GBP","LU1803068623.USD","IE0009G5SDU7.USD","LU0175139822.USD","LU1721428933.USD","LU0949170772.SGD","LU2746668461.USD","LU0472753341.HKD","BK4503","LU0211328371.USD","LU1267930490.SGD","BK4534","LU0320765992.SGD","LU2471134523.USD","IE0034235295.USD","SG9999014914.USD","LU1043141123.HKD","LU1506573853.SGD","LU1366192091.USD","LU2463028550.USD","LU1003077747.HKD","IE0002141913.USD","LU1935042488.USD","LU1316542783.SGD","LU2213496289.HKD","LU1894683264.USD","LU0690374615.EUR","BK4507","LU2491050154.USD","LU0823417653.USD","BK4007","LU1571399168.USD","LU2023250843.SGD","LU1868837300.USD","LU1430594728.SGD","LU0109392836.USD","LU1988902786.USD","SG9999014898.SGD","IE00BN8TJ469.HKD","LU0289739699.SGD","LU0742534661.SGD","LU1066051225.USD","LU0128525929.USD","SG9999000418.SGD","LU1551013342.USD","LU0690374961.EUR","LU1852331112.SGD","LU0642271901.SGD","LU2097829019.USD","LU0289960550.SGD","LU1244550221.USD","LU2413666426.HKD","LU2247934214.USD","LU1642822529.SGD","LU2360108059.USD","IE0002270589.USD","LU2092937221.SGD","IE00BMPRXR70.SGD","LU0157215616.USD","LU0130102774.USD","LU2125154778.USD","BK4533","LU1674673691.USD","LU1718418525.SGD","LU2552382058.USD","LU0310799852.SGD","IE00B19Z9505.USD","IE00BWXC8680.SGD","LU1037948897.HKD","IE00BJT1NW94.SGD","LU0965508806.USD","LU0106261372.USD","LU1564329115.USD","LU2023251221.USD","LU0187121727.USD","LU0965509101.SGD","LU0348723411.USD","SG9999014880.SGD","LU0545039389.USD","LU0345769631.USD","IE00BFTCPJ56.SGD","LU2361044949.HKD","BK4525","LU2764263039.SGD","LU0353189680.USD","LU1023059063.AUD","LU2023250330.USD","LU2097344357.USD","LU0823421416.USD","LU2896262040.SGD","LU0029864427.USD","LU0784385170.HKD","BK4579","BK4524","LU0256863902.USD","IE000YTNTUN2.SGD","LU0170899867.USD","LU1236620834.HKD","LU2065170008.USD","LU1069347547.HKD","LU0980610538.SGD","LU0784384876.USD","LU1989764664.SGD","LU1496350171.SGD","LU0069063385.USD","LU1697837992.HKD","LU2746668974.SGD","LU2065169927.USD","LU1989764748.USD","LU0792757196.USD","LU1564329461.SGD","LU0353189763.USD","LU1301847155.USD","LU2756315664.SGD","LU2471134796.USD","LU1989773731.SGD","LU0823421333.USD","SGXZ51526630.SGD","LU1153585028.USD","LU0267386448.USD","LU0879622024.SGD","LU0795875169.SGD","LU2041044095.USD","LU1983260115.SGD","LU0719512351.SGD","SG9999017495.SGD","LU0943347566.SGD","LU2089284900.SGD","LU0234570918.USD","LU0312595415.SGD","LU2506952170.USD","SG9999002224.SGD","LU0080751232.USD","IE0009355771.USD","LU1334329650.SGD","LU0476273544.USD","LU2210149790.SGD","LU2362541513.USD","IE00B775SV38.USD","RZLT","LU2458330169.SGD","IE00BN29S564.USD","LU0882574139.USD","LU2506951958.HKD","LU1670711040.USD","LU0320765489.SGD","LU2491050071.SGD","LU0823416689.USD","LU0949170426.SGD","LU2236285917.USD","LU1582987324.SGD"],"gpt_icon":1}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}